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a  b  s  t  r  a  c  t
Systemic erythematosus lupus (SLE) is a multisystemic autoimmune disease which has
nephritis as one of the most striking manifestations. Although it can coexist with other
autoimmune diseases, and determine the predisposition to various infectious complica-
tions, SLE is rarely described in association with non-lupus nephropathies etiologies. We
report the rare association of SLE and primary IgA nephropathy (IgAN), the most frequent
primary glomerulopathy in the world population. The patient was diagnosed with SLE due
to  the occurrence of malar rash, alopecia, pleural effusion, proteinuria, ANA 1: 1280, nuclear
ﬁne speckled pattern, and anticardiolipin IgM and 280 U/mL. Renal biopsy revealed mesan-
gial hypercellularity with isolated IgA deposits, consistent with primary IgAN. It was treated
with antimalarial drug, prednisone and inhibitor of angiotensin converting enzyme, show-
ing  good progress. Since they are relatively common diseases, the coexistence of SLE and
IgAN may in fact be an uncommon ﬁnding for unknown reasons or an underdiagnosed con-
dition. This report focus on the importance of the distinction between the activity of renal
disease in SLE and non-SLE nephropathy, especially IgAN, a deﬁnition that has important
implications on renal prognosis and therapeutic regimens to be adopted in both the short
and long terms.
© 2014 Elsevier Editora Ltda. All rights reserved.
Nefropatia  por  IgA  em  paciente  portadora  de  lúpus  eritematoso
sistêmico:  relato  de  caso  e  revisão  de  literatura
r  e  s  u  m  oPalavras chave:
Lúpus eritematoso sistêmico
Nefropatia por IgA
Glomerulonefrite
O lúpus eritematoso sistêmico (LES) é uma doenc¸a autoimune multissistêmica que tem
como uma das manifestac¸ões mais marcantes a nefrite. Apesar de poder coexistir com out-
ras  doenc¸as autoimunes e determinar a predisposic¸ão a diversas complicac¸ões infecciosas,
o  LES raramente é descrito em associac¸ão a nefropatias de etiologia não lúpica. Relatamos
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o caso da rara associac¸ão entre LES e nefropatia por IgA (NIgA) primária, a glomerulopa-
tia  primária mais frequente na populac¸ão mundial. A paciente foi diagnosticada com LES
pela  ocorrência de eritema malar, alopecia, derrame pleural, proteinúria, pancitopenia, FAN
1:1.280 padrão nuclear pontilhado ﬁno e anticardiolipina IgM 280 U/mL. A biópsia renal rev-
elou  hipercelularidade mesangial com depósitos isolados de IgA, compatível com NIgA
primária. Foi tratada com antimalárico, prednisona e inibidor da enzima conversora de
angiotensina e apresentou boa evoluc¸ão. Por consistirem em doenc¸as relativamente fre-
quentes, a coexistência de LES e NIgA pode ser de fato um achado incomum por motivos
desconhecidos ou uma condic¸ão subdiagnosticada. Este relato atenta para a importância
da  distinc¸ão entre a atividade de doenc¸a renal do LES e nefropatias não lúpicas, em espe-
cial  a NIgA, deﬁnic¸ão que tem implicac¸ões importantes sobre o prognóstico renal e regimes
terapêuticos a serem adotados em curto e longo prazo.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Fig. 1 – Optical microscopy of specimen obtained by renal
biopsy revealing mesnagial expansion and hypercelullarityntroduction
ystemic lupus erythematosus (SLE) is a chronic disease of
he connective tissue characterized by a number of immuno-
ogical disorders which result in the onset of inﬂammatory
esion in various organ tissues. Lupus nephritis (LN) is the
ost common visceral manifestation of SLE, being diagnosed
n approximately 37–45% of the patients at some time dur-
ng the course of the disease in the Brazilian population.1,2
he description of nephritis of other etiologies in patients
iagnosed with SLE, however, is an uncommon ﬁnding.3 IgA
ephropathy (IgAN), although being the most common cause
f glomerulopathy in general population,4 is rarely associated
ith SLE.5–10 We  reported a case of rare coexistence of IgAN in
 patient with SLE.
ase  report
orty-year-old female patient, complaining of generalized
dema six months ago, associated with polyarthralgias,
ntermittent fever, alopecia, weight loss of 7 kg, and ulcerated
esion on the right leg. On examination the patient was pale,
ith bilateral periorbital edema, facial ﬂushing, reduced
esicular murmur on the right, lower limb edema (2+/4+)
nd pyoderma gangrenosum in the middle third of the right
eg, associated with stiffness and swelling of the right calf.
dditional assessment indicated hemoglobin of 8.9 g/dL,
eukopenia, mild thrombocytopenia, ANA 1:1.280 of nuclear
ne speckled pattern, CH50 of 88 U/mL, C3 of 46 mg/dL,
4 of 9 mg/dL, negative anti-dsDNA, anticardiolipin IgM of
11 U/mL, proteinuria of 1045 mg/24 h, endogenous creatinine
learance of 162 mL/min, dysmorphic hematuria, and granular
rinary casts. Chest computed tomography showed bilateral
leural effusion, mild pericardial effusion, and ascites. Lower
imb Doppler ultrasonography ruled out thrombotic event.
enal biopsy was performed, showing 16 intact glomeruli
ith mesangial granular deposition of IgA, negative for othermmune deposits, and mesangial hypercellularity (Fig. 1).
he patient was diagnosed with SLE associated with IgAN,
nd she was initially treated with prednisone 60 mg/day,
ydroxychloroquine 400 mg/day, enalapril 10 mg/day, and(HE, 200×).
supplementation of calcium and vitamin D, and antibiotics
for skin lesion. After initiating treatment, the patient showed
improvement of the joint, cutaneous, hematologic, and renal
status, being ready for hospital discharge.
Discussion
SLE is a disease marked by heterogeneity of clinical pheno-
types and unpredictable course.1,2 These properties make the
characterization of the disease, the acknowledgment of its
complications, and the detection of overlying conditions a
constant challenge in the routine of rheumatology services.
The classic clinical presentation of LN is persistent protein-
uria and/or cellular casts, or active urinary sediment, i.e., ﬁve
or more  red blood cells or leukocytes per high power ﬁeld.
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Laboratory data may indicate SLE and LN activity, speciﬁ-
cally as high titers of anti-dsDNA antibodies and complement
consumption.11
The IgAN, on the other hand, manifests itself as persistent
microscopic, or sporadic macroscopic hematuria, with ﬂare
triggered by inﬂammatory stress. Proteinuria and other ﬁnd-
ings may or may not be present, and serum complement levels
are typically normal.12
Due to the relative frequency of both conditions, the coex-
istence of primary IgAN and SLE can be an occasional ﬁnding.
Both LN and IgAN are conditions which are characterized by
disorders of immune function, with the presence of circulating
immune complexes and anti-C1q antibodies, in addition to the
involvement of genetic and environmental risk factors.12–14
It is still uncertain whether the rarity of the association of
SLE with non-lupus nephritis occurs due to a protective factor
presented by patients with SLE, or if we  face underdiagnosed
conditions.3,8,10 The coexistence of SLE and IgAN has been
recently described, with only eight cases published in the
world so far,5–10 with this being the ﬁrst case reported in
Brazil. Mac-Moune et al. ﬁrst reported this association in 1995,5
with three patients who, similar to the one here in Brazil,
had glomerular lesion of indolent course associated with exu-
berant systemic presentations. Curiously, Basile et al. and
Kobak et al.6,10 described patients who, besides the diagno-
sis of IgAN and SLE, had Hashimoto’s thyroiditis, a relatively
common association with SLE, but that rarely coexists with
IgAN.
The patient described was admitted to our hospital with
a suggestive multisystemic clinical picture, and antibody
proﬁle consistent with the diagnosis of SLE. The identiﬁ-
cation of histopathological ﬁndings suggestive of IgAN in
SLE patients was, as in most of the cases reported in the
literature,5,6,8,10 from renal biopsy indicated for histological
classiﬁcation of probable LN. On two occasions the diagno-
sis of IgAN was suggested in patients with no SLE activity.7,9
This fact can point to an IgAN ﬂare determined by the sys-
temic inﬂammatory insult, a common characteristic of the
disease,12 in this case caused by SLE. Most of the described
cases revealed normal complement, a factor favoring the diag-
nosis of IgA nephropathy. In contrast, the patient described
herein, as well as those published by Corrado et al. and
Kobak et al.8,10 showed complement consumption at diag-
nosis, possibly reﬂecting extrarenal lupus activity, such as
the hematologic activity reported here. Another common fea-
ture among the cases described is the indolent course of
IgAN, with urinary sediment changes, variable proteinuria,
and preservation of glomerular ﬁltration, with immunosup-
pressive therapy, when it is undertaken, being indicated due
to extrarenal lupus activity.5,6,8,10
Histopathological examination showed mesangial hyper-
cellularity and glomerular deposition of IgA in the absence
of other immune deposits. The immunohistological ﬁndings
of IgAN include mesangial deposits of IgA, C3, and pos-
sibly, IgG and IgM in lesser extent.12 On the other hand,
the LN characteristic changes include glomerular, vascular
and tubulointerstitial lesions with deposition of polyclonal
immunoglobulins, mainly IgG, and fractions of complement
C1q, C3 and C4.14 Although mesangial IgA deposition can be
considered a subtype of LN, the absence of IgG, C1q, C3 and
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C4 deposits is not an expected ﬁnding in LN,  being more  com-
patible with the diagnosis of IgAN.5,6,12
The distinction between IgAN and LN in SLE patients
has important prognostic and therapeutic implications.
The general recommendations for treatment of IgAN
are focused on blood pressure control and proteinuria
reduction with antihypertensive drugs that act on the
renin–angiotensin–aldosterone system, with immunosup-
pression being reserved to cases of crescentic glomeru-
lonephritis, and corticosteroid therapy for limited time only
in patients with persistent proteinuria greater than 1 g/24 h
even after 3–6 months of optimized therapy.15 On the other
hand, in the treatment for LN, besides controlling protein-
uria and blood pressure, base therapy with antimalarials for
all patients is recommended, as well as speciﬁc protocols of
immunosuppression according to the histopathological class
of the disease.11
Finally, this report highlights the possibility of overex-
posure of primary IgAN in patients with SLE, which is an
association that may be more  common than it is frequently
described in the literature, and has direct implications on the
follow-up and treatment of these individuals with the short-,
medium- and long-term complications.
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